Delcath Systems, Inc. (Nasdaq: DCTH), a New York-based interventional oncology company, announced on Thursday that it has introduced a Healthcare Setting Locator (Locator) on the hepzatokit.com website.

Potential patients, caregivers, and healthcare providers are expected to utilise the Locator to identify healthcare settings, providing treatment with the HEPZATO KIT, a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Sites included on the Locator are accepting inquiries from patients or their physicians seeking potential treatment with HEPZATO KIT. These sites either have or expect to have completed all training and internal approvals necessary to treat a patient following the normal screening for eligibility.

Kevin Muir, Delcath's general manager of US Interventional Oncology, said, 'The Healthcare Setting Locator, which the Company will update periodically, is an important tool to assist patients, their caregivers, and their healthcare providers, as they consider appropriate treatment. The previously announced establishment of the permanent J-Code for HEPZATO (J9248) and the launch of the Locator are two important steps in providing information and access to patients for this treatment.'